Postoperative Hypofractionated Intensity-modulated Radiotherapy Endometrial Cancer
Not Applicable
Recruiting
- Conditions
- Endometrial Cancer
- Interventions
- Radiation: POHIM_EM
- Registration Number
- NCT05876130
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
To investigate the non-inferiority of disease-free survival in women who received hypofractionated intensity-modulated whole pelvic radiation therapy (2.5 Gy x 16 fractions) after curative surgery for stage III endometrial cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 92
Inclusion Criteria
- histologically confirmed endometrioid type endometrial cancer
- completion of hysterectomy and surgical staging
- pathologically confirmed FIGO stage III
- ECOG performance status 0 or 1
- adjuvant chemotherapy was done or planned
Exclusion Criteria
- presence of distant metastasis
- previous history of pelvic radiotherapy
- severe and unstable medical condition
- previous history of other carcinoma except for thyroid cancer, skin cancer, and endometrial cancer
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description POHIM_EM POHIM_EM adjuvant hypofractionated IMRT for endometrial cancer
- Primary Outcome Measures
Name Time Method 5-year disease-free survival rate 5 years disease-free survival rate after the time of surgery
- Secondary Outcome Measures
Name Time Method acute toxicities 3 months acute toxicities within 3 months according to CTCAE v5.0
late toxicities 5 years late toxicities according to CTCAE v5.0
Trial Locations
- Locations (1)
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of